Loading
NASDAQHealthcareMedical - Care Facilities
Latest quote
$6.63
+$0.45 · +7.28%
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Previous close
$6.63
+$0.45 · +7.28%
Regular session · ET · Market data may be delayed.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Day range
Current $6.63
52-week range
Current $6.63
Regular session · ET · Market data may be delayed.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Day range
Current $6.63
52-week range
Current $6.63
| Metric (USD) | FY2025 |
|---|---|
| Revenue | 502.73M USD |
| Cost of goods sold | 426.29M USD |
| Gross profit | 76.44M USD |
| Selling, general, and administrative | 105.57M USD |
| Operating expenses | 112.52M USD |
| Interest expense | 11.28M USD |
| Depreciation and amortization | 6.94M USD |
| Operating income | −36.08M USD |
| Net income | −60.61M USD |
Company facts updated Oct 11, 2026.
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI14.16M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM12.64M0.02%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF4.75M0.00%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO3.39M0.02%13.92B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2.6M0.01%18B USD0.06%$112.66+0.50%
State Street SPDR S&P Health Care Services ETFXHS2.4M1.17%204.46M USD0.35%$136.26+1.22%
iShares Micro-Cap ETFIWC1.49M0.11%1.32B USD0.60%$183+0.11%
Vanguard Health Care ETFVHT1.2M0.01%22B USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOState Street SPDR S&P Health Care Services ETFXHSiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
